Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

  • Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical genome mapping (OGM) and findings from early access customers
  • The pre-conference event will also include a 2024 corporate overview from Bionano’s chief executive officer, Dr. Erik Holmlin, presentations from Dr. Brynn Levy at Columbia University Medical Center, Dr. Ulrich Broeckel at Medical College of Wisconsin, Dr. Susan Crocker at Kingston Health Sciences Centre, Dr. Liz McCready at Hamilton Health Science Center, and Dr. Zeid Hamadeh at Vancouver General Hospital covering the utility of OGM and VIA™ software and the adoption, implementation, and advanced research capabilities of the Stratys system, and will conclude with a fireside chat with panelists hosted by Bionano’s chief medical officer, Dr. Alka Chaubey
  • In a sponsored session, Dr. Chaubey will cover findings from large multi-site clinical studies using OGM as well as features of the Stratys system. Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
  • A scientific platform presentation will feature Drs. Hamadeh and Spence discussing OGM’s utility for the genotyping of hematological neoplasms
  • Dr. Holmlin will participate with Dr. Nancy Mendelsohn, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by Bionano
  • Eleven scientific posters featuring results from OGM applications in cancer, postnatal applications and genetic disorders will be presented at the conference

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2024 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including cancer, rare genetic disease and constitutional disorders. ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.

All scientific posters will be presented in Exhibit Halls DE. Poster presentations and scientific workshop sessions on OGM include:

Poster Number   Title   Authors Presented
P573   Genome-wide short tandem repeat expansion screening using optical genome mapping   Yu J. March 14, 2024
10:30 AM-12:00 PM ET
P583   Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup of hematological malignancies   Toruner G. March 14, 2024
10:30 AM- 12:00 PM ET
P839   A curated research catalogue of structural variation detected by optical genome mapping   Pang A. March 14, 2024
10:30 AM-12:00 PM ET
P088   A comprehensive approach to evaluate genetic abnormalities in plasma cell neoplasms using optical genome mapping and next-generation sequencing   Zou Y. March 15, 2024
10:30 AM-12:00 PM ET
P608   Optical genome mapping for genome-wide structural variation analysis in hematologic malignancies: results of a prospective study and potential impact on diagnosis and management   Sahoo T. March 15, 2024
10:30 AM-12:00 PM ET
P656   Improved diagnostic paradigm using optical genome mapping (OGM) for cytogenomic testing for recurrent pregnancy loss and infertility  

Crocker S.

March 15, 2024
10:30 AM-12:00 PM ET
P694   Case report: unraveling a complex chromosomal rearrangement case using optical genome mapping  

Ozcan Z.

March 15, 2024
10:30 AM- 12:00 PM ET
P742   Assessing stability of frozen samples for Bionano optical single DNA mapping for diagnosis of Facioscapulohumeral Muscular Dystrophy Type 1   Cook S. March 15, 2024
10:30 AM-12:00 PM ET
P746   Genome wide, high-throughput, high-resolution structural variation detection at low variant allele fraction for oncology samples   Hastie A. March 15, 2024
10:30 AM-12:00 PM ET
P842   Unified comprehensive analysis of NGS and optical genome mapping data for constitutional applications using Bionano VIA™ software   Norgaard Z. March 15, 2024
10:30 AM-12:00 PM ET
P850   Accelerated optical genome mapping analysis with Stratys Compute and Guided Assembly   Senol Cali D. March 15, 2024
10:30 AM-12:00 PM ET
Session   Title   Presenter Presented
Sponsored Workshop   LIVE Bionano product showcase – Stratys™ revealed: exclusive first look at the future of OGM   Chaubey A., Broeckel U., Crocker S., Hamadeh Z., Holmlin E., Jiandani D., Levy B., McCready L., Sahoo T. March 12, 2024
8:00 AM- 12:30 PM ET
Delta Hotel by Marriott- Kensington Ballroom
Plenary Session  

2024 ACMG Foundation Awards and Presidential Plenary Session

  Holmlin E. March 13, 2024
10:00-12:00 PM ET
Exhibit Hall FG
Platform Presentation   A Canadian lab’s clinical validation experience with optical genome mapping as a front-line diagnostic test for hematological neoplasms   Hamadeh Z., Spence T. March 14, 2024
4:15-5:45 PM ET
MTCC- 714/716
Sponsored Workshop   Revolutionizing cytogenomics with Stratys™: unveiling a new frontier in structural variant assessment through optical genome mapping at scale   Chaubey A., Spence T., March 15, 2024
10:45-11:15 AM ET
Exhibit Theater 2

Erik Holmlin, PhD, president and chief executive officer of Bionano, added, “We are proud to debut our new high throughput system for OGM, Stratys, at ACMG this year, and to host sessions featuring customers from our Stratys early access program presenting data from work conducted on the system. Researchers and scientists continue to push forward cutting-edge research in the human genetics space and we believe the capabilities of the Stratys system will unlock even more exciting research advancements. We look forward to these customers sharing their findings with the ACMG community.”

More details on Bionano’s conference events can be found here.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Bionano’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Bionano offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, Bionano also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Bionano also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Bionano additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology.

Forward-Looking Statements of Bionano

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s utility for applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2024 Annual Meeting; the ability of the Stratys system to unlock research advancements; and the growth and adoption of OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including bank failures, inflation and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM to prove useful in areas including applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s Annual Meeting; failure of the Stratys system to unlock research advancements; failure of laboratories to adopt OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625


error: Content is protected !!